How to buy Black Diamond Therapeutics stock | $33.38

Black Diamond Therapeutics, Inc is a biotechnology business based in the US. Black Diamond Therapeutics shares (BDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Black Diamond Therapeutics employs 58 staff and has a market cap (total outstanding shares value) of USD$1.2 billion.

How to buy shares in Black Diamond Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Black Diamond Therapeutics. Find the stock by name or ticker symbol: BDTX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Black Diamond Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$33.38, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Black Diamond Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Black Diamond Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Black Diamond Therapeutics share price

Use our graph to track the performance of BDTX stocks over time.

Black Diamond Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$33.38
52-week range	USD$17.63 - USD$45.9699
50-day moving average	USD$33.4561
200-day moving average	USD$32.5201
Wall St. target price	USD$51
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.0803

Buy Black Diamond Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Black Diamond Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Black Diamond Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Black Diamond Therapeutics price performance over time

Historical closes compared with the close of $33.38 from 2020-12-09

1 week (2021-01-15)	23.90%
1 month (2020-12-23)	-1.21%
3 months (2020-10-23)	4.77%
6 months (2020-07-22)	17.54%

1 year (2020-01-19)	N/A
2 years (2019-01-19)	N/A
3 years (2018-01-19)	N/A
5 years (2016-01-19)	N/A

Black Diamond Therapeutics financials

Gross profit TTM	USD$0
Return on assets TTM	-16.6%
Return on equity TTM	-27.02%
Profit margin	0%
Book value	N/A
Market capitalisation	USD$1.2 billion

TTM: trailing 12 months

Shorting Black Diamond Therapeutics shares

There are currently 3.0 million Black Diamond Therapeutics shares held short by investors – that's known as Black Diamond Therapeutics's "short interest". This figure is 4.8% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting Black Diamond Therapeutics shares can be evaluated.

Black Diamond Therapeutics's "short interest ratio" (SIR)

Black Diamond Therapeutics's "short interest ratio" (SIR) is the quantity of Black Diamond Therapeutics shares currently shorted divided by the average quantity of Black Diamond Therapeutics shares traded daily (recently around 307364.37941473). Black Diamond Therapeutics's SIR currently stands at 9.91. In other words for every 100,000 Black Diamond Therapeutics shares traded daily on the market, roughly 9910 shares are currently held short.

However Black Diamond Therapeutics's short interest can also be evaluated against the total number of Black Diamond Therapeutics shares, or, against the total number of tradable Black Diamond Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Black Diamond Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Black Diamond Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1176% of the tradable shares (for every 100,000 tradable Black Diamond Therapeutics shares, roughly 118 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Black Diamond Therapeutics.

Find out more about how you can short Black Diamond Therapeutics stock.

Black Diamond Therapeutics share dividends

We're not expecting Black Diamond Therapeutics to pay a dividend over the next 12 months.

Black Diamond Therapeutics overview

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Black Diamond Therapeutics is owned by insiders or institutions?

  Currently 4.759% of Black Diamond Therapeutics shares are held by insiders and 86.092% by institutions.

• How many people work for Black Diamond Therapeutics?

  Latest data suggests 58 work at Black Diamond Therapeutics.

• When does the fiscal year end for Black Diamond Therapeutics?

  Black Diamond Therapeutics's fiscal year ends in December.

• Where is Black Diamond Therapeutics based?

  Black Diamond Therapeutics's address is: 139 Main Street, Cambridge, MA, United States, 02142

• What is Black Diamond Therapeutics's ISIN number?

  Black Diamond Therapeutics's international securities identification number is: US09203E1055

• What is Black Diamond Therapeutics's CUSIP number?

  Black Diamond Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09203E105